Company Overview and News


Add IDRA
to your dashboard

Headline News

Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors

2017-11-21 marketwired
BOSTON, MA--(Marketwired - November 21, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has been appointed Chairman of the Board of Directors. Mr. Geraghty replaces Chau Q. Khuong, who is stepping down from the Board after helping guide Pieris through platform validation and partnerships to its transition into a fully-integrated research and clinical development company. (118-1)

Is the Options Market Predicting a Spike in Idera (IDRA) Stock?

2017-11-10 zacks
Investors in Idera Pharmaceuticals, Inc. (IDRA - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $4 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (73-0)

IDRA / Idera Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-10-31 fintel.io
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has 80 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 54,821,190 shares. Largest shareholders include Baker Brothers Advisors LP, BlackRock Inc., Vanguard Group Inc, Broadfin Capital, LLC, and FMR LLC / Fidelity Management & Research. (104-1)

Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health

2017-09-18 prnewswire
If you want a Stock Review on GALE, IDRA, RXDX, or JAGX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,448.47, up 0.30%; the Dow Jones Industrial Average edged 0.29% higher, to finish at 22,268.34; and the S&P 500 closed at 2,500.23, marginally gaining 0.18%. Gains were broad based as six out of nine sectors finished the trading session in green. (207-4)

Ionis Absorbs Glaxo Rare Disease Cull

2017-08-14 seekingalpha
From Ionis Pharmaceuticals' (NASDAQ:IONS) perspective, Glaxosmithkline's (NYSE:GSK) decision to opt out of its collaboration on inotersen and Ionis-FB-LRX is not the worst outcome that could befall it. After all, Glaxo had paid $35m seven years ago to secure rights for up to six Ionis antisense assets, and along the way kicked in more than $50m in collaboration revenue for a clinical program that required fewer than 200 patients to be filing ready in TTR amyloidosis.

Week 26 Breakout Forecast Short-Term Picks To Give You An Edge

2017-06-25 seekingalpha
Last week portfolio returned 3.24% for the week compared to S&P 500 -0.62% for the week

3 Stocks That Could Double Your Money

2017-06-24 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-1)

3 Stocks to Watch on Friday: Bed Bath & Beyond Inc. (BBBY), Sonic Corporation (SONC) and Idera Pharmaceuticals Inc (IDRA)

2017-06-23 investorplace
The U.S. stock market posted slight losses Thursday as the day’s focus turned to the Senate health bill, which will come to a vote next week. The S&P 500 Index and the Dow Jones Industrial Average lost 0.1% apiece, while the Nasdaq Composite gained a fraction of a percentage by day’s end.

Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors

2017-05-22 marketwired
BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight.

Here's Why Idera Pharmaceuticals, Inc. Is Sinking Today

2017-05-05 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

After Strong Early Market Performance, Tocagen Could Pop At Its Quiet Period Expiration

2017-05-01 seekingalpha
IPO quiet period for TOCA expires on 5.8; on 5.9 underwriters Evercore, Leerink, and Stifel will likely release positive reports.

Biotech Forum Daily Digest: Neurocrine's Big Win; Spotlight On Idera Pharmaceuticals

2017-04-13 seekingalpha
The biotech sector continues to drift aimlessly within a tight trading range and almost all movement across the sector is currently due to company specific news and events.

3 Things In Biotech You Should Learn Today: April 12, 2017

2017-04-12 seekingalpha
Welcome to another installment of "3 Things in Biotech You Should Learn Today," a series dedicated to helping expose the material events that impact on a wide range of biotech outlets. Today, we're sticking with oncology, as we have some more straggling news out of AACR that may have missed your radar. Beyond that, we have some new developments, both good and bad, for Bristol-Myers Squibb (NYSE:BMY) and small Idera Therapeutics (NASDAQ:IDRA).

Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma Nasdaq:IDRA

2017-04-11 globenewswire
CAMBRIDGE, Mass. and EXTON, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announces successful completion of the phase 1 portion of the ongoing Phase 1/2 clinical trial of intratumoral IMO-2125. Intratumoral IMO-2125 is an agonist of TLR9, in combination with ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma.

Stock Research Report

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera Pharmaceuticals use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its third-generation antisense, or 3GA, technology. Idera Pharmaceuticals developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera Pharmaceuticals design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using its 3GA technology, Idera Pharmaceuticals is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera Pharmaceuticals believe its 3GA technology may potentially reduce the immunoto...

Click for full article
CUSIP: 45168K306